![Guy MacDonald](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 51 384 $ al 30/06/2026
Guy MacDonald is currently Chairman at SCYNEXIS, Inc. since 2015.
Former roles include Chairman at F-Star Therapeutics, Inc. (United States) from 2014 to 2015, Director at Tetraphase Pharmaceuticals, Inc. in 2019, Vice President-Anti Infective & Hospital Products at Merck & Co., Inc. in 2003, and Executive Vice President-Operations at Idenix Pharmaceuticals LLC from 2003 to 2008.
Education includes an undergraduate degree from the University of Dundee.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SCYNEXIS, INC. 0,13 % | 26/06/2026 | 12.625 ( 0,13 % ) | 51 384 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SCYNEXIS, INC. | Presidente | 04/06/2015 |
| Empresas | Cargo | Fin |
|---|---|---|
| TETRAPHASE PHARMACEUTICALS, INC. | Director Ejecutivo | 01/08/2019 |
| SPRING BANK PHARMACEUTICALS, INC. | Presidente | 17/08/2015 |
| IDENIX PHARMACEUTICALS INC | Director de Operaciones | 01/01/2008 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2003 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for the treatment of human viral and infectious diseases caused by hepatitis | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
SCYNEXIS, Inc.
 SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
University Of Dundee
 University Of Dundee Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology Engages in discovery, development and preparation of bioavailable therapeutics | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
